A detailed history of Man Group PLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Man Group PLC holds 469,844 shares of CPRX stock, worth $10.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
469,844
Previous 619,411 24.15%
Holding current value
$10.7 Million
Previous $9.87 Million 26.29%
% of portfolio
0.02%
Previous 0.03%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$14.68 - $16.92 $2.2 Million - $2.53 Million
-149,567 Reduced 24.15%
469,844 $7.28 Million
Q1 2024

May 15, 2024

SELL
$13.18 - $17.11 $326,929 - $424,413
-24,805 Reduced 3.85%
619,411 $9.87 Million
Q4 2023

Feb 14, 2024

SELL
$11.78 - $17.29 $416,552 - $611,391
-35,361 Reduced 5.2%
644,216 $10.8 Million
Q3 2023

Nov 14, 2023

SELL
$11.69 - $15.02 $1.82 Million - $2.33 Million
-155,431 Reduced 18.61%
679,577 $7.94 Million
Q2 2023

Aug 14, 2023

SELL
$11.5 - $18.08 $745,372 - $1.17 Million
-64,815 Reduced 7.2%
835,008 $11.2 Million
Q1 2023

May 15, 2023

BUY
$14.34 - $21.05 $147,572 - $216,625
10,291 Added 1.16%
899,823 $14.9 Million
Q4 2022

Feb 14, 2023

BUY
$12.25 - $19.5 $1.25 Million - $2 Million
102,432 Added 13.01%
889,532 $16.5 Million
Q3 2022

Nov 14, 2022

BUY
$7.06 - $15.52 $3.41 Million - $7.49 Million
482,300 Added 158.23%
787,100 $10.1 Million
Q2 2022

Aug 15, 2022

BUY
$6.23 - $8.57 $303,401 - $417,359
48,700 Added 19.02%
304,800 $2.14 Million
Q1 2022

May 16, 2022

SELL
$5.31 - $8.31 $726,408 - $1.14 Million
-136,800 Reduced 34.82%
256,100 $2.12 Million
Q4 2021

Feb 14, 2022

BUY
$5.21 - $7.45 $453,270 - $648,150
87,000 Added 28.44%
392,900 $2.66 Million
Q2 2021

Aug 16, 2021

SELL
$4.29 - $6.05 $250,222 - $352,878
-58,327 Reduced 16.01%
305,900 $1.76 Million
Q1 2021

May 17, 2021

SELL
$3.45 - $4.69 $2.17 Million - $2.95 Million
-629,335 Reduced 63.34%
364,227 $1.68 Million
Q4 2020

Feb 16, 2021

SELL
$2.97 - $3.83 $420,255 - $541,945
-141,500 Reduced 12.47%
993,562 $3.32 Million
Q3 2020

Nov 16, 2020

BUY
$2.97 - $5.08 $253,421 - $433,461
85,327 Added 8.13%
1,135,062 $3.37 Million
Q2 2020

Aug 14, 2020

BUY
$3.48 - $5.05 $3.28 Million - $4.75 Million
941,435 Added 869.28%
1,049,735 $4.85 Million
Q1 2020

May 15, 2020

BUY
$2.61 - $5.21 $90,045 - $179,745
34,500 Added 46.75%
108,300 $417,000
Q4 2019

Feb 18, 2020

BUY
$3.67 - $5.7 $270,846 - $420,660
73,800 New
73,800 $277,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.34B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.